Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
Would you consider a cisplatin-based regimen with hypofractionated radiation for bladder cancer?
Are there any prospective studies?
Answer from: Radiation Oncologist at Community Practice
Yes, with bladder only RT almost any chemo regimen is acceptable, including cisplatinum, Gemzar, or 5FU and MMC.
Sign in or Register to read more
7181
Related Questions
How do you design pelvic lymph node treatment volumes for patients with tortuous or aberrant vascular anatomy?
When treating prostate cancer with moderate hypo-fractionation, what urethral dose constraints do you consider when boosting the dominate intraprostatic lesion?
Does long term use of 5 alpha reductase inhibitors change the way you evaluate a PSMA PET?
How would you treat a patient with a post prostatectomy biochemical and pelvic nodal recurrence with a BLM mutation?
Would you consider re-irradiation for a prostate local failure for a patient who initially received standard fractionation with a focal SIB to 95 Gy, or a SBRT boost with cyberknife after EBRT?
Are there any contraindications to Pluvicto therapy you personally use, given that there are none directly provided by the manufacturer?
How do you manage malignancies in patients with Birt-Hogg-Dubé syndrome (BHD)? Is there concern for increased radiosensitivity?
How would you approach de novo metastatic castrate sensitive prostate cancer with extensive locoregional spread causing rectal compression, retroperitoneal lymphadenopathy, and PSA >3000 but no visceral or bone metastases?
What dose-fractionation do you use for salvage HDR brachytherapy for biopsy proven locally recurrent prostate cancer after prior external beam radiotherapy?
In a patient with a synchronous prostate cancer and non-invasive urothelial carcinoma limited to the prostatic urethra is complete TUR and definitive prostate dose to standard prostate fields adequate treatment?